HEMATOLOGIC ONCOLOGY

血液肿瘤学

• 批准号: 6664388
• 负责人: Stephen D. Nimer
• 金额: $ 18.86万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6664388
• 关键词: acute myelogenous leukemia; amidohydrolases; antineoplastics; antitumor antibody; arsenic; autologous transplantation; blood /lymphatic neoplasm; chronic myelogenous leukemia; enzyme inhibitors; human subject; human therapy evaluation; monoclonal antibody; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer nutrition therapy; neoplasm /cancer radiation therapy; neoplasm /cancer therapy; neoplasm /cancer vaccine; nonHodgkin's lymphoma; nutrition related tag; patient oriented research; retinoate; stem cell transplantation

DESCRIPTION: (Applicant's Description) The overall aims of the Hematologic Oncology Project are to develop and test new and effective strategies for treating hematologic neoplasms using targeted therapies and biologic agents. The SPECIFIC AIMS for this revised proposal are to: Develop novel therapeutic strategies in hematologic malignancies, including a) histone deacetylase inhibitors, such as depsipeptide b) geldanamycin in the treatment of CML c) desoxyepothiline B in the treatment of non-Hodgkin's Iymphoma. Evaluate the use of targeted therapies using: a)monoclonal antibodies in dose-intense strategies, with autologous stem cell support for myeloid leukemias and myelodysplastic syndromes, using a radio labeled humanized monoclonal antibody (HuMl95; anti-CD33) to deliver targeted radiotherapy b)monoclonal antibodies for treatment of minimal residual disease in acute promyelocytic leukemia using all-trans retinoic acid for induction, followed by unlabeled HuM195, arsenic trioxide, and then idarubicin for consolidation c) ''tumor-specific'' vaccine approaches in patients with peptide vaccine in patients with myelodysplastic syndromes or AML. Evaluate tumor specific endpoints using a)Correlative in vitro assays of HDAC inhibition b) Serial quantitative levels of BCR-ABL protein (or rnRNA) c) MR Spectroscopy to assess response (for d) RT-PCR based assays to detect residual APL cells.

描述：（申请人的描述）血液学的总体目标 肿瘤学项目将开发和测试新的有效策略 使用靶向疗法和生物制剂治疗血液肿瘤。 该修订提案的具体目标是： 开发新的治疗方法 血液系统恶性肿瘤的治疗策略，包括 a) 组蛋白脱乙酰酶 治疗中使用抑制剂，例如缩肽 b) 格尔德霉素 c) 脱氧埃坡霉素 B 在治疗非霍奇金病中的作用 淋巴瘤。 使用以下方法评估靶向治疗的使用：a) 单克隆抗体 剂量密集型策略，利用自体干细胞支持骨髓细胞 白血病和骨髓增生异常综合征，使用标记为人性化的无线电 单克隆抗体（HuM195；抗CD33）以提供靶向放射治疗 b) 用于治疗微量残留的单克隆抗体 使用全反式维A酸治疗急性早幼粒细胞白血病 诱导，然后是未标记的 HuM195、三氧化二砷，然后 伊达比星用于巩固 c) “肿瘤特异性”疫苗方法 在骨髓增生异常患者中接种肽疫苗的患者 综合征或 AML。 使用 a)HDAC 相关体外测定评估肿瘤特异性终点 b) BCR-ABL 蛋白的连续定量水平 （或 mRNA） c) MR 波谱法评估反应（对于 d) 基于 RT-PCR 的检测残留 APL 细胞的检测。